Bayer Buys Rights to Isis Pharma’s Blood Thinner for Up to $155 Million
Bayer announces that it will pay up to $155 million, plus royalties, for the rights to Isis Pharma’s anti-clotting drug, ISIS-FXI.
Bayer announced on May 4, 2015 that it would pay $100 million upfront, with the potential of an additional $55 million, to Isis Pharma for its blood-thinner ISIS-FXIRX. The additional $55 million is subject to the success of a Phase II study in patients with compromised kidney function.
According to Reuters, Bayer plans to evaluate ISIS-FXIRX in patients that are unable to receive other blood thinners due to a high risk of bleeding, and has plans to look into more uses for the drug in anticoagulation. Isis is also eligible to receive milestone payments and tiered royalties “in the low- to high-twenty percent range on gross margins of ISIS-FXI” writes Reuters.
According to Isis’ website, data exhibits evidence that the drug prevents clotting without increasing bleeding, unlike other anticoagulants. The drug targets a clotting factor, called Factor XI, produced in the liver, which aides in coagulation and of which high levels increase the risk for clotting.
Source: Reuters
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
How Smart Technology is Helping Reach Sustainability Goals in Drug Packaging
June 7th 2025Smart technologies, such as digital and laser printing, incorporated into manufacturing equipment are helping manufacturers align with sustainability goals, according to Sheikh Akbar Ali, general manager and head of Development and Technology for ACG Packaging Materials.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
